Our industry-recognized Education team is committed to sharing program findings, best practices, insights, and trends from our educational programs across a range of therapeutic areas. These findings are regularly published in peer-reviewed journals, as well as presented at medical, patient, and industry conferences.
PlatformQ Health had 20 posters accepted at major medical and healthcare conferences during 2022. We’re pleased to share the posters, highlighting key outcomes from our educational initiatives across an array of therapeutic areas. Oncology 2022 Alliance Industry Summit Supplemental Digital Resources CME Program Closes Critical Knowledge Gap in Cancer Immunotherapy...
Patients with chronic spontaneous urticaria (CSU) often suffer with unresolved symptoms, despite numerous visits to different healthcare providers. In a recent poster presented at the 2023 American Academy of Allergy, Asthma, and Immunology, PlatformQ Health evaluated the impact of digital continuing medical education (CME) on optimizing diagnosis as well as...
Gastric or gastroesophageal junction (GEJ) adenocarcinomas are notoriously difficult to treat, but recently approved immune checkpoint inhibitors and HER2-directed antibody drug conjugates are improving outcomes for patients with these conditions. While these advances are a positive change, they do pose challenges for healthcare providers who need to learn about new...
Vast racial disparities exist in triple-negative breast cancer (TNBC), yet many patients and providers are aware of these issues. Women of the African Diaspora (WAD) are often diagnosed at a more advanced stage and experience higher rates of TNBC-related mortality. Though the TNBC treatment landscape has changed with the influx...
Targeted treatment regimens have significantly improved overall survival for patients with chronic lymphocytic leukemia (CLL). The emergence of new options such as BTK inhibitors has shifted the treatment landscape significantly, bringing a pressing need for education for providers, patients, and caregivers. This included a persistent need for: A better understanding...
The growth of immunotherapies has shifted the standard of care for treating many solid tumors. As new indications are approved, there is a growing need for clinician education in this space. To that end, the Society for Immunotherapy of Cancer (SITC) and PlatformQ Health partnered to develop a two-part educational...
Early diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) are key to reducing patients' risk, yet there is low awareness of current guidelines and treatment options among healthcare practitioners. To address these challenges, the American Society for Preventive Cardiology, Mended Hearts, Mended Little Hearts, the National Lipid Association, and PlatformQ Health...
Targeted therapies have allowed for better management of neuroendocrine tumors (NETs), yet this requires that healthcare providers glean new knowledge about treatment options such as somatostatin analogs. To improve provider competency and include consideration of patient perspectives in treatment selection, PlatformQ Health and Healing NET Foundation teamed up with the...
Patients often face an epic journey of many years before receiving a diagnosis for a rare disease. With nearly one in 10 Americans impacted by a rare condition, it is essential that we decrease the time to diagnosis to improve the lives of these individuals and their families. To that...
ASCO Quality Care Symposium 2022: Patient Voice Helps Improve Point-of-Care for Urothelial Carcinoma
Targeted therapies such as immune checkpoint inhibitors are poised to improve long-term survival of patients with urothelial carcinoma. The emergence of these new therapies, however, presents knowledge gaps for clinicians, prompting PlatformQ Health and the Bladder Cancer Advocacy Network (BCAN) to create an unique education series for urology and oncology...
Using standard therapeutic regimens for patients with myasthenia gravis (mGM) is often complicated by multiple comorbidities. New targeted agents may lessen treatment burdens. To address these challenges, PlatformQ Health, the National Organization for Rare Disorders, and the Myasthenia Gravis Foundation of America produced online continuing medical education for health care...
Primary mitochondrial disease (PMD) is often missed by clinicians due to the broad range of clinical presentations and genetic etiologies. Our recent program "Progressive Myopathy: Could it be a Genetic Mitochondrial Disease?" focused on diagnosing this condition in infants, children, and adults who present with progressive muscle weakness; understanding the...